Guangdong Xiangxue Life Sciences (XLifeSc) is a biomedical company focused on TCR-based therapies for cancer. Our main technological platform is TCR Affinity Enhancing Specific T Cell Therapy (TAEST) . Our product is a kind of autologous T cell product genetically modified by TCR. It is a kind of TCR-T cellular immunotherapy drugs which has relatively high clinical efficacy and safety. Such product can recognize the intracellular and extracellular tumor-specific antigens. In addition, it has longer retention time in vivo due to the immunological memory function and therefore it has more obvious therapeutic effects in the solid tumor field compare to CAR-T. In recent years, a series of data of many study sites have also proved the considerable efficacy of TCR-T cell therapy for treatment of solid tumors.
Our main technologies include (1) the identification of tumor-specific antigen peptides, (2) the cloning of tumor antigen-specific TCRs, and (3) the optimization of antigen-specific TCRs in terms of affinity and stability, etc, which have been protected with independently-owned intellectual property portfolio.
By collaborating with a number of highly-recognized medical centers in China, we have conducted several PI-initiated clinical trials on various indications such as non-small cell lung cancer, synovial sarcoma and other types of solid tumors, which have showed encouraging efficacy and safety profile.
We have obtained investigational new drug (IND) approval for our product TAEST16001 from NMPA in China, and now we are in the progress of recruiting patients. This is the first IND approval in the field of TCR-T cell therapies in China.
Over the years, XLifeSc has recruited several top-notch research scientists from renowned companies and institutes around the world. With ample experience in immunology, protein engineering, genetic engineering, bioprocessing, and viral production, XLifeSc’s glamorous scientific team is able to generate a sustainable TCR-T pipeline .
Housing several state-of-the-art laboratories, XLifeSc can offer a broad range of R&D services, including (1) target identification and lead optimization; (2) efficacy validation and safety testing in cell lines and animal models; (3) clinical trial development; and (4) market entry planning. These capabilities and services can be either accessed as flexible stand-alone services on demand or as a part of integrated discovery programs. With our validated platforms, you can reserve products from our existing or potential pipelines.
On the path toward a fully integrated pharmaceutical company, we are relentlessly seeking out partnership opportunities to explore avenues that could potentially further consolidate our long-term strategic goal of becoming a leading global player in the sector of precision medicine. We welcome all types of alliance opportunities such as out-license, co-development, and co-marketing. XLifeSc has out-licensed overseas market rights of TAEST16001 to Axis Therapeutics, which is a new joint venture established by XLifeSc and Athenex, Inc (NASDAQ:ATNX).